Clinical Trial Update: Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating prevention of UV-induced carcinogenic skin alterations in immunosuppressed solid organ transplant patients was terminated, with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis
• Squamous Cell Carcinoma

Snippet

Sponsor: Spirig Pharma Ltd. | Conditions: Actinic Keratoses, Squamous Cell Carcinomas | Phase 3 | Status: TERMINATED | Results posted: 2016-01-08